Replies to post #164009 on Innovation Pharmaceuticals Inc (IPIX)

[scottsmith]

Unfortunately people can't have it both ways: either the Phase 1 is just about safety or the spleen lesion PR was pure pump by a unprofessional OTC CEO.

But as I've stated repeatedly, K is totally irrelevant for shareholders and really shouldn't be part of any discussion about current or future share price (at least within the next three years).

[BonelessCat]

I said Phase 1 trials are always focused on safety and that safety is always a primary endpoint. I didn't say anything about it being the only endpoint. If you reread the thread, I make that pretty clear. In fact, my discussion yesterday was to make that same point you make, that there is strong evidence of efficacy, and that one efficacy endpoint for Kevetrin was evidence of p53 modulation.

[sox040713]

You said some are trying to downplay K efficacy, but when I mentioned stable diseases in some ovarian patients, you said tumors can stabilize on its own so it doesn't mean anything. So I guess it just happened that the tumors spread to stage 4 prior to K and stabilize on its own during K treatment.

One of the secondary endpoints is p21 and 67.5% of patients had an increase in p21 expression. Unless you say p53 can reactivate on its own, I think it's safe to say that K reactivates p53. That's efficacy and CTIX reported it.

http://cellceutix.com/cellceutix-announces-database-lock-in-phase-1-trial-of-kevetrin-a-promising-new-cancer-treatment-that-activates-p53/#sthash.fCll3RME.dpbs

Before a tumor can shrink, it has to stop growing first. Before a tumor can stop growing, p53 has to be reactivated first. K P1 confirmed the first step. With more frequent dosing in P2, hopefully tumors can start shrinking.